Jaguar health announces submission of orphan drug designation application to the fda for crofelemer for cholera-related diarrhea

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium vibrio cholerae crofelemer previously granted orphan drug designation by the fda and the ema for both short bowel syndrome and microvillus inclusion disease san francisco, ca / accesswire / february 12, 2024 / jaguar health (nasdaq:jagx) today announced that jaguar family company napo pharmaceuticals (napo) has submitted an orphan drug designation (odd) application to the u.s. food and drug administration (fda) for crofelemer, the company's novel plant-based prescription drug, for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral, and parasitic infections including vibrio cholerae, the bacterium that causes cholera. due to the very low incidence and prevalence of cholera in the united states, cholera is an orphan indication in this country.
JAGX Ratings Summary
JAGX Quant Ranking